Financial reports
ARS
2023 FY
Annual report to shareholders
19 Apr 24
10-K
2023 FY
Annual report
13 Mar 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
ARS
2022 FY
Annual report to shareholders
17 Apr 23
10-K
2022 FY
Annual report
22 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Other Events
25 Mar 24
8-K
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
13 Mar 24
8-K
Other Events
6 Feb 24
8-K
Departure of Directors or Certain Officers
19 Jan 24
8-K
Other Events
13 Dec 23
8-K
Other Events
3 Nov 23
8-K
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
1 Nov 23
8-K
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
8 Aug 23
8-K
Departure of Directors or Certain Officers
2 Jun 23
8-K
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
26 Apr 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
25 Mar 24
S-8
Registration of securities for employees
8 Aug 23
424B5
Prospectus supplement for primary offering
7 Mar 23
S-8
Registration of securities for employees
23 Feb 23
POS AM
Prospectus update (post-effective amendment)
23 Feb 23
POSASR
Automatic shelf registration (post-effective amendment)
22 Feb 23
424B5
Prospectus supplement for primary offering
23 Dec 22
S-3ASR
Automatic shelf registration
5 May 21
S-8
Registration of securities for employees
15 Oct 20
424B5
Prospectus supplement for primary offering
6 Aug 20
Proxies
DEF 14A
Definitive proxy
19 Apr 24
PRE 14A
Preliminary proxy
3 Apr 24
DEF 14A
Definitive proxy
17 Apr 23
PRE 14A
Preliminary proxy
5 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
1 Apr 22
DEF 14A
Definitive proxy
2 Apr 21
DEFA14A
Additional proxy soliciting materials
8 May 20
DEF 14A
Definitive proxy
2 Apr 20
PRE 14A
Preliminary proxy
23 Mar 20
Other
EFFECT
Notice of effectiveness
24 Apr 23
CT ORDER
Confidential treatment order
3 Feb 20
CT ORDER
Confidential treatment order
26 Feb 19
CT ORDER
Confidential treatment order
26 Feb 19
CT ORDER
Confidential treatment order
26 Feb 19
CT ORDER
Confidential treatment order
3 Dec 18
CT ORDER
Confidential treatment order
25 Jun 18
CT ORDER
Confidential treatment order
26 Apr 18
CT ORDER
Confidential treatment order
12 Sep 17
EFFECT
Notice of effectiveness
9 Jun 17
Ownership
SC 13G/A
WASATCH ADVISORS LP
5 Apr 24
4
Amy Pooler
27 Feb 24
4
Scott B. Willoughby
27 Feb 24
4
Nathalie Dubois-Stringfellow
27 Feb 24
4
Prathyusha Duraibabu
27 Feb 24
4
Sandy Macrae
27 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BIOGEN INC.
12 Feb 24
SC 13G/A
WASATCH ADVISORS LP
9 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24